Cargando…

Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis

Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by a lipid-driven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bin, Li, Weihong, Li, Xiaoli, Zhou, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302344/
https://www.ncbi.nlm.nih.gov/pubmed/28034355
http://dx.doi.org/10.2174/1381612822666161230142931
_version_ 1783381958831636480
author Li, Bin
Li, Weihong
Li, Xiaoli
Zhou, Hong
author_facet Li, Bin
Li, Weihong
Li, Xiaoli
Zhou, Hong
author_sort Li, Bin
collection PubMed
description Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by a lipid-driven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, treatment targeting the inflammatory nature of atherosclerosis is still very limited and deserves further attention to fight atherosclerosis successfully. Here, we review the current development of inflammation and atherosclerosis to discuss novel insights and potential targets in atherosclerosis, and to address drug discovery based on anti-inflammatory strategy in atherosclerotic disease.
format Online
Article
Text
id pubmed-6302344
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-63023442019-01-14 Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis Li, Bin Li, Weihong Li, Xiaoli Zhou, Hong Curr Pharm Des Article Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by a lipid-driven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, treatment targeting the inflammatory nature of atherosclerosis is still very limited and deserves further attention to fight atherosclerosis successfully. Here, we review the current development of inflammation and atherosclerosis to discuss novel insights and potential targets in atherosclerosis, and to address drug discovery based on anti-inflammatory strategy in atherosclerotic disease. Bentham Science Publishers 2017-03 2017-03 /pmc/articles/PMC6302344/ /pubmed/28034355 http://dx.doi.org/10.2174/1381612822666161230142931 Text en © 2017 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Li, Bin
Li, Weihong
Li, Xiaoli
Zhou, Hong
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
title Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
title_full Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
title_fullStr Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
title_full_unstemmed Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
title_short Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
title_sort inflammation: a novel therapeutic target/direction in atherosclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302344/
https://www.ncbi.nlm.nih.gov/pubmed/28034355
http://dx.doi.org/10.2174/1381612822666161230142931
work_keys_str_mv AT libin inflammationanoveltherapeutictargetdirectioninatherosclerosis
AT liweihong inflammationanoveltherapeutictargetdirectioninatherosclerosis
AT lixiaoli inflammationanoveltherapeutictargetdirectioninatherosclerosis
AT zhouhong inflammationanoveltherapeutictargetdirectioninatherosclerosis